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Introduction: N-methyl-D-aspartate receptor (NMDAR) antago-
nists are used for postsurgery neuropathic pain states, but severe side 
effects limit their clinical use. Memantine, when given after surgery, 
shows contradictory results as regards neuropathic pain alleviation.
Patients (or Materials) and Methods: Memantine is administered 
in animals before or after spinal nerve ligation (SNL) to evaluate 
the antinociceptive/cognitive effects and associated molecular events 
(including phosphorylated-Tyr1472NR2B subunit). SNL animals 
received memantine or saline 4 days before (pre-emptive) or after 
surgery (postoperative) for 7 days, were tested for tactile allodynia, 
mechanical hyperalgesia, cognitive function and spinal cord molecu-
lar events, and results were compared (significance P < 0.05).
Results: Postoperative memantine had no beneficial effect on tac-
tile allodynia, mechanical hyperalgesia, or spatial memory, and 
molecular expression of NR2B subunit was significantly increased. 
Pre-emptive memantine prevented the development of mechanical 
hyperalgesia, tactile allodynia, and impairment of spatial memory; 
spinal pTyr1472NR2B was not increased.
Conclusion: Blockade of NMDAR by memantine 4 days before sur-
gery rather than postoperatively is a promising strategy in animals to 
alleviate neuropathic pain development and impairment of cognitive 
function. The pivotal role of pTyr1472NR2B must be studied further, 
and confirmation of these findings in patients would constitute a 
giant footstep in the prevention of neuropathic pain that frequently 
follows surgical procedures.
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Introduction: With > 25% of the American population experiencing 
daily pain and the number of new drugs still in the single-digit area, it 
is becoming more and more of an important health problem to come 
up with new or improved analgesis compounds. Our paper proposes 
a new approach for obtaining an efficient controlled-release system 
for the pain treatment via inovative polymeric nanoparticles by using 
an interfacial condensation method between a natural polymer, chi-
tosan (CS) and a synthetic one (poly (maleic anhydride -alt -vinyl 
acetate), (poly (MAVA).
Patients (or Materials) and Methods: Chitosan, acetone, Ibuprofen 
(IBU), hexane, and surfactants were used (Sigma Aldrich). The alter-
nant copolymer – poly (MAVA) was synthesized by radical copolym-
erization and characterized in our laboratory. The nanocapsules were 
characterized and investigated by Fourier transform infrared spec-
troscopy (FTIR), Scanning Electron Microscope (SEM), Transmission 
Electron Microscope (TEM), thermogravimetric analysis (TGA), and 
differential scanning calorimetry (DSC). In vitro IBU loading and 
release was also investigated. In vivo testing of IBU/nanocapsules 
was evaluated by hot plate test and tail flick test, behavioral tests 
that quantify the thermal nociception. Adult male Swiss mice in dif-
ferent groups of 8 mice each were intraperitoneally injected with 
one of the following formulations: 0.9% saline for a control group; 
ibuprofen for positive control group (100 mg/kg b.w.); ibuprofen-
loaded nanocapsules (MAVA-CS-9) for test group (100 mg/kg b.w. 
equivalent ibuprofen). Inhibition to pain stimuli was then calculated.
Results: Zeta potential determinations indicated a good stability of 
the nanocapsules in aqueous solutions. Scanning electron micros-
copy confirmed the nanometric dimensions and the spherical shape 
of the nanocapsules. The thermal properties achieved by DSC and 
ATG showed the nanocapsules’ good thermal stability. In addition, 
these systems present a good swelling capacity, which is influenced by 
the reaction parameters taken into account in this study. The drug-
loading and -release capacity (studied for ibuprofen sodium salt used 
as water-soluble drug) is controlled by the diffusion speed through 
the polymeric membrane and is influenced by the swelling degree. 
Although ibuprofen alone has a half-life of 1 to 3 hours, and previ-
ous studies showed an analgesic improvement of their nanoparticle 
formulations in the 1- to 2-hour range, our system has a time interval 
of 2 to 6 hours of analgesic efficacy, an increase of up to 6 times the 
reference ibuprofen formulation.
Conclusion: We have proved the possibility of a sustained-release 
system for central pain inhibition (from 2 to 24 hours) versus 0 to 
2 hours ibuprofen control. Future variations in the ibuprofen load 
of the nanocapsules could yield potentially significant commercial 
applications with improved efficacy and safety profiles.
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Introduction: It known that bile acids improve the absorption, bio-
availability, and pharmacodynamic characteristics of some drugs. 
Because morphine analgesia is produced by activation of opioid 
receptors within the central nervous system at both spinal and 
supraspinal levels, and because morphine molecule contains 3 polar 
groups, and as such is hard to transfer through the blood-brain bar-
rier, the aim of the study was to examine the potential influence 
of bile acids derivates, namely sodium salt of monoketocholic acid 
(MKH-Na) and methyl ester of monoketocholic acid (MKH-Me) on 
analgesic effect of morphine.
Patients (or Materials) and Methods: White male mice of NMRI-
Haan strain, with body weight of 20 to 24 g, were used in this study. 
Analgesic effect of morphine was estimated by the hot plate method. 
Analgesic effect of morphine (2 mg/kg) (administered by subcutane-
ous and intramuscular route of administration) with and without 
pretreatment with MKH-Na (4 mg/kg) and MKH-Me (4 mg/kg) was 
measured.
Results: Administration of MKH-Me before subcutaneous admin-
istration of morphine increased the morphine analgesic effect, but 
the increase was not statistically significant. At the same time the 
administration of MKH-Na did not affected morphine analgesic 
effect. Analgesic effect of morphine was increased when morphine 
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was administered intramuscularly 20 minutes after MKH-Me admin-
istration. When compared with group of animals treated only with 
morphine, statistically significant increase in analgesic effect was 
detected 10, 30, 40, and 50 minutes after morphine administration 
(P < 0.05). Pretreatment with MKH-Na did not affect morphine 
analgesic effect.
Conclusion: According to results of this study, it can be presumed 
that after intramuscular morphine administration methyl ester of 
monoketocholic acid increases morphine transport into the central 
nervous system and consequently analgesic effect as well. Further 
research on bile acids-morphine interaction both in vitro and in vivo 
is necessary to completely elucidate the mechanism of this interaction 
and increase in morphine analgesic effect.
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Introduction: Bile acids (BAs) are essential for the absorption, trans-
port, and distribution of dietary lipids, vitamins, and xenobiotics. 
As transcription factor ligands (eg, of FXR), they influence signaling 
pathways regulating lipid, glucose, and energy homeostasis.1 First 
studies indicate that BAs are also able to influence the expression 
of microRNAs (miRNAs), a class of small noncoding RNAs that is 
able to inhibit protein translation.1,2 Several different hepatic disease 
states as well as the intake of certain hepatotoxic drugs can induce 
cholestasis, a condition associated with elevated bile acid levels in 
hepatocytes.
We aimed to comprehensively investigate the impact of BAs on 
the human mRNAome and miRNAome, focusing on the question, 
to which extent elevated BAs may have the potential to influence the 
expression of genes involved in drug metabolism and disposition and 
signaling pathways driven by miRNAs.
Patients (or Materials) and Methods: Two batches of primary 
human hepatocytes were treated with 50-µM chenodeoxycholic 
acid (CDCA) or vehicle (DMSO) for 48 hours. Global mRNA and 
miRNA profiling was performed using next-generation sequencing. 
Adapter-ligated RNA samples were reverse-transcribed and enriched 
by PCR. After cluster generation (TruSeq PE Cluster Kit v3-cBot-
HS (Illumina)) sequencing was performed on the Illumina HiSeq 
2000 (TruSeq SBS Kit v3-HS (Illumina)). RNA-reads were quality-
checked (fastqc) and aligned to the genome (tophat v1.3.3). The 
GLM procedure (edgeR, R package) was used for statistical analysis 
comparing the mRNA and miRNA expression values across the 
different conditions.
Results: A total of 702 genes were significantly decreased, 1345 
genes and 71 miRNAs were significantly increased in expression in 
BA-treated cells. Besides classical FXR targets involved in BA trans-
port and metabolism (eg, CYP7A1, BSEP) that served as positive 
controls for repression and induction by BAs, respectively, many 
genes coding for proteins involved in drug metabolism appear to be 
affected and in many cases down regulated by BAs. Examples include 
genes encoding members of the CYP1A, CYP2C and CYP3A and the 
SLC transporter family as well as members of the GST, SULT, and 
UGT family. Notably members of the miRNA families 320 and 548 
appeared to be strongly regulated by CDCA.
Conclusion: BAs have the potential to significantly modulate the 
expression of genes involved in the biotransformation of drugs and, 
thus, may have a significant impact on drug metabolism and dispo-
sition. The detection of differentially expressed miRNA molecules 
extends the spectrum of regulatory pathways influenced by BAs.
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Introduction: Liver dysfunction is frequent in CHF and characterized 
by a predominantly cholestatic enzyme profile that is associated with 
disease severity and prognosis. Thus, we propose a cardio-hepatic 
syndrome in CHF. Future studies are needed to clarify the exact 
mechanisms of organ interaction. The aim of the study was to evalu-
ate the efficacy of various therapy of CHF to cessation the symptoms 
of “cardio-hepatic” syndromes.
Patients (or Materials) and Methods: A total of 125 patients with 
IHD and CHF NYHA class II–III were enrolled in this open, con-
trolled trial. The protocol was approved by local ethical committee. 
All patients after randomization were included into group; control and 
main. In the control group, patients were treated by standard combina-
tion and in main group additionally received badci (NAD-containing 
drug) in dose of 180 mg once daily for 14 days. Symptoms of CHF, 
ECG, EchoCG, and markers of hepatic function were clinically com-
pared. Blood chemistry analysis included the measurements of circulat-
ing level of total and direct billirubin, ALT, AST, γ -glutamyltransferase 
(GGT), and alkaline phosphatase (ALP), NAD, NAD/NADH levels 
and the content of proinflammatory cytokines (IL-1 and IL 6) were 
studied. Data were analyzed with SPSS 10.0 statistical package.
Results: In patients with stable CHF without marked systolic dys-
function, changes of liver abnormalities were common by typically 
by small amplitude, particularly in those patients with an ejection 
fraction < 35%. Middle elevation of alkaline phosphatase and total 
billirubine as well as mild decrease of albumine were observed. The 
redox potential of NAD/NADH in the plasma was reduced by 21% 
without significantly changes in the total content of pyridine nucleo-
tide. We postulated that hypoxia might play a pathophysiologic role 
linking CHF to liver injury. The content of IL6 increase up to 112% 
in patients with average NYHA class 2.3 (0.2) (according to J. Cohn 
HF score, 1986) in the mechanism of which leads the ability of IL-6 
binds to hepatocytes by interacting with an 80-kd membrane gly-
coprotein (gp80). Including in the therapy NAD-containing drug, 
nadcin (180 mg once daily IV) significantly improved hepatic func-
tion and cholestatic abnormalities, and as very important decrease 
up to normal level the content of IL6 and IL-1β in patients with CHF 
without pronounced left ventricle dysfunction.
Conclusion: Cessation of abnormalities of the hematologic system 
and decrease in the content of IL-6, as 1 of the key regulators of 
the initial steps of liver regeneration and IL-6–dependent signal-
ing response mechanism under treatment with exogenous NAD-
containing drug (in form of nadcin) restores the cell redox-potential, 
occurs beneficial effect on the cytokine system and as a result occurs 
deremodeling of liver functioning system, opens the new era in the 
CHF therapy and avoid the cardio-hepatic syndrome formation.
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